Bringing together researchers from Italy and the US, Chroma Medicine has emerged out of stealth with series A financing led by Cormorant Asset Management.
Chroma Medicine, a US-based epigenetic editing technology developer exploiting research from multiple institutions, has launched with $125m in series A financing led by hedge fund Cormorant Asset Management.
Casdin Capital, Janus Henderson Investors, Omega Funds, funds and accounts advised by T Rowe Price Associates, Wellington Management, Atlas Venture, Newpath Partners and Sofinnova Partners all backed the round.
The latter three had previously provided seed capital, Chroma disclosed in its launch announcement without offering further details.
Founded in May 2020, Chroma Medicine is working on epigenetic editing technology – allowing it to turn genes on or off, or altering the expression the multiple genes at once.
The company has not disclosed specific diseases it is targeting, but the approach could have applications in a wide range of conditions. It will use the series A cash to further develop its platform and to advance a pipeline of assets.
Vic Myer was an…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
